It was identified through a medicinal chemistry programme at the University of Texas Health Science Center as the lead NNMT inhibitor candidate among a series of 1-methylquinolinium analogues bearing primary amine substitutions, selected for its combination of high passive membrane permeability (confirmed in PAMPA assays), high active transport membrane permeability (confirmed in bidirectional Caco-2 cell assays), potent NNMT inhibitory activity, and high selectivity including confirmed absence of inhibitory effects on related SAM-dependent methyltransferases or enzymes in the NAD+ salvage pathway
Immediate medical attention is warranted if missed periods are accompanied by concerning symptoms such as severe abdominal pain, heavy bleeding, abnormal vaginal discharge, signs of pregnancy, symptoms of thyroid dysfunction (significant fatigue, cold intolerance, hair loss), or signs of hyperprolactinaemia (galactorrhoea, visual disturbances, headaches)
Solubility: Soluble in water and buffered aqueous solutions
MECHANISM CATEGORIES SAFETY Side effects Generally well-tolerated in trials at the doses tested Injection-site reactions Known interactions Not characterized in Phase 3 Contraindications Pregnancy/lactation (unstudied) REGULATORY STATUS FDA Not FDA-approved as a drug
Most of the existing research comes from rodent studies
